AMO Pharma

AMO Pharma is a UK-based, private biotech founded in 2015, specializing in small molecule therapeutics for rare and orphan diseases. The company is building a focused pipeline of clinical-stage assets, with key programs in congenital myotonic dystrophy (CDM) and Phelan-McDermid syndrome, aiming to address vast unmet needs in these underserved patient populations. Led by a team of seasoned industry professionals, AMO Pharma employs a patient-centric business model designed to deliver value through efficient drug development and commercialization. Its strategy targets the significant opportunity within the rare disease space, where only a small fraction of known conditions have approved therapies.

Business development platform focused on acquiring and advancing clinical-stage small molecule assets for rare diseases, leveraging expertise in orphan drug development, regulatory strategy, and patient-centric trial design.

Competition varies by indication; for Congenital Myotonic Dystrophy and Phelan-McDermid Syndrome, the landscape may include other small biotechs or academic efforts, but approved therapies are currently absent, making it a high-need space. The primary competition is often the standard of care, which is supportive management rather than disease-modifying treatment.